{"schema_version":"secwatch.filing_event.v1","accession":"0001625101-22-000065","form_type":"8-K","ticker":"PLSE","cik":"0001625101","company_name":"PULSE BIOSCIENCES, INC.","filed_at":"2022-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.480767+00:00","generated_at":"2026-06-21T23:03:51.817659+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Pulse Biosciences reports Q3 net loss $18M, tightens focus on cardiac ablation, secures $65M loan from chairman","bullets":["Q3 GAAP net loss $18.0M vs $14.3M in prior year; no revenue recorded.","Strategic pivot to cardiac cellular ablation for atrial fibrillation; dermatology business inventory reserve of $7.2M.","Entered $65M term loan at 5% interest, due March 2024, from Executive Chairman Robert Duggan.","Appointed Kevin Danahy as CEO, Darrin Uecker as CTO, and Robert Duggan as Executive Chairman.","Anticipates quarterly cash burn ~$8M from Q1 2023; cash $69.2M at Sep 30 vs $28.6M at Dec 31, 2021."],"urls":{"canonical":"https://secwatch.observer/filing/0001625101-22-000065","json":"https://secwatch.observer/filing/0001625101-22-000065.json","markdown":"https://secwatch.observer/filing/0001625101-22-000065.md","text":"https://secwatch.observer/filing/0001625101-22-000065.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1625101/000162510122000065/0001625101-22-000065-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1625101/000162510122000065/plse-20221110x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T23:03:51.817659+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3fa1691409174d0076ec37aa9ea6956927e88629","claim":"PULSE BIOSCIENCES, INC. reported financial results for the third quarter ended September 30, 2022.","evidence_excerpt":"On November 10, 2022, Pulse Biosciences, Inc. announced its financial results for the fiscal quarter ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1625101/000162510122000065/0001625101-22-000065-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}